PCI Biotech Holding ASA

PCI Biotech Holding ASA is a biotechnology company focused on the commercialization and development of novel therapeutics. The primary function of PCI Biotech is to enhance drug delivery using its proprietary photochemical internalization (PCI) technology, which aims to improve the efficacy of existing drug treatments. This innovative technology has potential applications across various areas of unmet medical needs, including oncology and vaccines, making it a pivotal player in the biopharmaceutical sector. By overcoming the barriers of cellular uptake and controlling drug release, PCI Biotech's solutions hold promise to significantly impact the treatment landscapes of diseases that require more effective therapeutic options. The company's strategy is to leverage its technology through collaborative alliances with other pharmaceutical entities, thus amplifying its role in the global market. Headquartered in Oslo, PCI Biotech is strategically positioned in a growing industry, supported by a robust focus on research and development, making it a company of interest for stakeholders in the health and pharmaceutical markets.